 Tamoxifen
"Tamoxifen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.
| Descriptor ID |
D013629
|
| MeSH Number(s) |
D02.455.426.559.389.150.700.900
|
| Concept/Terms |
Soltamox- Soltamox
- Savient brand of Tamoxifen Citrate
ICI-46474- ICI-46474
- ICI 46474
- ICI46474
- ICI-46,474
- ICI 46,474
- ICI46,474
|
Below are MeSH descriptors whose meaning is more general than "Tamoxifen".
Below are MeSH descriptors whose meaning is more specific than "Tamoxifen".
This graph shows the total number of publications written about "Tamoxifen" by people in this website by year, and whether "Tamoxifen" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 2 | 0 | 2 | | 1982 | 0 | 1 | 1 | | 1983 | 1 | 2 | 3 | | 1984 | 1 | 0 | 1 | | 1985 | 0 | 3 | 3 | | 1986 | 0 | 1 | 1 | | 1987 | 0 | 1 | 1 | | 1988 | 0 | 2 | 2 | | 1989 | 1 | 1 | 2 | | 1990 | 0 | 1 | 1 | | 1992 | 1 | 1 | 2 | | 1993 | 0 | 1 | 1 | | 1995 | 0 | 1 | 1 | | 1996 | 2 | 2 | 4 | | 1997 | 3 | 0 | 3 | | 1998 | 2 | 0 | 2 | | 1999 | 1 | 3 | 4 | | 2000 | 1 | 2 | 3 | | 2001 | 3 | 2 | 5 | | 2002 | 1 | 0 | 1 | | 2003 | 2 | 2 | 4 | | 2004 | 3 | 3 | 6 | | 2005 | 0 | 2 | 2 | | 2006 | 3 | 1 | 4 | | 2007 | 0 | 1 | 1 | | 2008 | 3 | 3 | 6 | | 2009 | 1 | 1 | 2 | | 2010 | 3 | 2 | 5 | | 2011 | 7 | 2 | 9 | | 2012 | 3 | 2 | 5 | | 2013 | 7 | 3 | 10 | | 2014 | 5 | 5 | 10 | | 2015 | 3 | 3 | 6 | | 2016 | 6 | 3 | 9 | | 2017 | 1 | 3 | 4 | | 2018 | 3 | 1 | 4 | | 2019 | 2 | 2 | 4 | | 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Tamoxifen" by people in Profiles.
-
Ribi K, Luo W, Walley BA, Burstein HJ, Chirgwin J, Ansari RH, Salim M, van der Westhuizen A, Abdi E, Francis PA, Chia S, Harvey VJ, Giobbie-Hurder A, Fleming GF, Pagani O, Di Leo A, Colleoni M, Gelber RD, Goldhirsch A, Coates AS, Regan MM, Bernhard J. Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy. Breast Cancer Res Treat. 2020 Jun; 181(2):347-359.
-
Pagani O, Francis PA, Fleming GF, Walley BA, Viale G, Colleoni M, Láng I, Gómez HL, Tondini C, Pinotti G, Di Leo A, Coates AS, Goldhirsch A, Gelber RD, Regan MM. Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT. J Clin Oncol. 2020 04 20; 38(12):1293-1303.
-
Martín M, Loibl S, Hyslop T, De la Haba-Rodríguez J, Aktas B, Cirrincione CT, Mehta K, Barry WT, Morales S, Carey LA, Garcia-Saenz JA, Partridge A, Martinez-Jañez N, Hahn O, Winer E, Guerrero-Zotano A, Hudis C, Casas M, Rodriguez-Martin C, Furlanetto J, Carrasco E, Dickler MN. Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials. Eur J Cancer. 2019 08; 117:91-98.
-
Goetz MP, Suman VJ, Nakamura Y, Kiyotani K, Jordan VC, Ingle JN. Tamoxifen Metabolism and Breast Cancer Recurrence: A Question Unanswered by CYPTAM. J Clin Oncol. 2019 08 01; 37(22):1982-1983.
-
Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE, Dees EC, Goetz MP, Olson JA, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW. Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. N Engl J Med. 2019 06 20; 380(25):2395-2405.
-
Fanning SW, Jeselsohn R, Dharmarajan V, Mayne CG, Karimi M, Buchwalter G, Houtman R, Toy W, Fowler CE, Han R, Lainé M, Carlson KE, Martin TA, Nowak J, Nwachukwu JC, Hosfield DJ, Chandarlapaty S, Tajkhorshid E, Nettles KW, Griffin PR, Shen Y, Katzenellenbogen JA, Brown M, Greene GL. The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells. Elife. 2018 11 29; 7.
-
Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, Gómez HL, Tondini C, Ciruelos E, Burstein HJ, Bonnefoi HR, Bellet M, Martino S, Geyer CE, Goetz MP, Stearns V, Pinotti G, Puglisi F, Spazzapan S, Climent MA, Pavesi L, Ruhstaller T, Davidson NE, Coleman R, Debled M, Buchholz S, Ingle JN, Winer EP, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Goldhirsch A, Regan MM. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med. 2018 Jul 12; 379(2):122-137.
-
Maximov PY, Abderrahman B, Fanning SW, Sengupta S, Fan P, Curpan RF, Rincon DMQ, Greenland JA, Rajan SS, Greene GL, Jordan VC. Endoxifen, 4-Hydroxytamoxifen and an Estrogenic Derivative Modulate Estrogen Receptor Complex Mediated Apoptosis in Breast Cancer. Mol Pharmacol. 2018 08; 94(2):812-822.
-
Goetz MP, Sangkuhl K, Guchelaar HJ, Schwab M, Province M, Whirl-Carrillo M, Symmans WF, McLeod HL, Ratain MJ, Zembutsu H, Gaedigk A, van Schaik RH, Ingle JN, Caudle KE, Klein TE. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Clin Pharmacol Ther. 2018 05; 103(5):770-777.
-
Rein LA, Wisler JW, Kim J, Theriot B, Huang L, Price T, Yang H, Chen M, Chen W, Sipkins D, Fedoriw Y, Walker JK, Premont RT, Lefkowitz RJ. ß-Arrestin2 mediates progression of murine primary myelofibrosis. JCI Insight. 2017 12 21; 2(24).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|